osimertinib,gefitinib
Astrazeneca
['apple trial']
 presenting the apple trial. monitoring t790m did not change overall survival compared to scans, but offered prognostic information based on clearance #esmo22 
Medical Oncologist, Translational Researcher, Peter Mac. Tweets are my own opinions. Musician (@mayhemtomi) https://t.co/f3ccD2Ml7v